Financials in USD. Standardized financial statements.
A compact view of how Revance Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $234.04M | $132.56M | $77.80M | $15.32M | $413,000 | $3.73M | $262,000 | $300,000 | $300,000 | $383,000 |
| Revenue Growth? | +76.5% | +70.4% | +407.7% | +3610.7% | -88.9% | +1323.3% | -12.7% | 0.0% | -21.7% | 0.0% |
| Cost of Revenue? | $152.16M | $51.67M | $23.41M | $4.77M | $102.86M | $92.50M | $0 | $0 | $2.00M | $0 |
| Gross Profit? | $81.88M | $80.90M | $54.39M | $10.56M | -$102.45M | -$88.77M | $262,000 | $300,000 | -$1.70M | $383,000 |
| Gross Margin? | +35.0% | +61.0% | +69.9% | +68.9% | -24805.8% | -2380.6% | +100.0% | +100.0% | -565.0% | +100.0% |
| Operating Expenses? | $398.65M | $353.07M | $329.06M | $283.72M | $164.87M | $146.36M | $117.76M | $79.46M | $72.62M | $52.43M |
| Operating Income? | -$316.78M | -$272.17M | -$274.68M | -$273.16M | -$164.46M | -$142.63M | -$120.42M | -$88.22M | -$72.32M | -$52.05M |
| EBITDA? | -$290.64M | -$305.52M | -$255.18M | -$259.31M | -$156.52M | -$137.80M | -$118.66M | -$86.74M | -$70.29M | -$50.00M |
| Income Before Tax | -$323.69M | -$355.72M | -$281.31M | -$284.71M | -$159.43M | -$139.57M | -$120.59M | -$89.27M | -$73.48M | -$62.92M |
| Income Tax Expense | $300,000 | $700,000 | $0 | -$2.62M | $0 | $3.00M | $0 | $0 | $0 | $0 |
| Net Income? | -$323.99M | -$356.42M | -$286.82M | -$282.09M | -$156.22M | -$142.57M | -$120.59M | -$89.27M | -$73.48M | -$62.92M |
| EPS? | $-3.83 | $-4.90 | $-4.25 | $-4.86 | $-3.59 | $-3.94 | $-4.01 | $-3.18 | $-3.02 | $-3.24 |
| Diluted EPS? | $-3.83 | $-4.90 | $-4.25 | $-4.86 | $-3.59 | $-3.94 | $-4.01 | $-3.18 | $-3.02 | $-3.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality